carbamates has been researched along with MPTP Neurotoxicity Syndrome in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Escamilla-Ramírez, A | 1 |
| García, E | 1 |
| Palencia-Hernández, G | 1 |
| Colín-González, AL | 1 |
| Galván-Arzate, S | 1 |
| Túnez, I | 1 |
| Sotelo, J | 1 |
| Santamaría, A | 1 |
| Johnston, TH | 1 |
| Huot, P | 1 |
| Fox, SH | 1 |
| Wakefield, JD | 1 |
| Sykes, KA | 1 |
| Bartolini, WP | 1 |
| Milne, GT | 1 |
| Pearson, JP | 1 |
| Brotchie, JM | 1 |
2 other studies available for carbamates and MPTP Neurotoxicity Syndrome
| Article | Year |
|---|---|
URB597 and the Cannabinoid WIN55,212-2 Reduce Behavioral and Neurochemical Deficits Induced by MPTP in Mice: Possible Role of Redox Modulation and NMDA Receptors.
Topics: Animals; Benzamides; Benzoxazines; Carbamates; Corpus Striatum; Dopamine; Down-Regulation; Lipid Per | 2017 |
Fatty acid amide hydrolase (FAAH) inhibition reduces L-3,4-dihydroxyphenylalanine-induced hyperactivity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned non-human primate model of Parkinson's disease.
Topics: Amides; Amidohydrolases; Animals; Benzamides; Callithrix; Carbamates; Disease Models, Animal; Dyskin | 2011 |